BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38774604)

  • 1. An On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reflects Short-Term Efficacy of PD-1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer.
    Liu J; Mao Y; Mao C; Wang D; Dong L; Zhu W
    J Immunol Res; 2024; 2024():3604935. PubMed ID: 38774604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.
    Hou Y; Li X; Yang Y; Shi H; Wang S; Gao M
    Front Immunol; 2023; 14():1274431. PubMed ID: 38022654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer.
    Qi Q; Peng Y; Zhu M; Zhang Y; Bao Y; Zhang X; Zhang J; Liu Y
    Int Immunopharmacol; 2023 Jan; 114():109553. PubMed ID: 36516540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer.
    Jiang R; Cheng X; Li P; Meng E; Wu X; Wu H
    Sci Rep; 2024 Jun; 14(1):14027. PubMed ID: 38890392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy.
    Wu L; Xie S; Wang L; Li J; Han L; Qin B; Zhang G; Wu Q; Gao W; Zhang L; Wei H; Liu T; Jiao S
    Front Immunol; 2021; 12():665147. PubMed ID: 33912192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
    Wang F; Wei XL; Wang FH; Xu N; Shen L; Dai GH; Yuan XL; Chen Y; Yang SJ; Shi JH; Hu XC; Lin XY; Zhang QY; Feng JF; Ba Y; Liu YP; Li W; Shu YQ; Jiang Y; Li Q; Wang JW; Wu H; Feng H; Yao S; Xu RH
    Ann Oncol; 2019 Sep; 30(9):1479-1486. PubMed ID: 31236579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum IL-5 and IFN-
    Zhao Q; Bi Y; Sun H; Xiao M
    Dis Markers; 2021; 2021():5526885. PubMed ID: 34239620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
    Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer.
    Chen Y; Wen S; Xia J; Du X; Wu Y; Pan B; Zhu W; Shen B
    Front Immunol; 2021; 12():672271. PubMed ID: 34054853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
    Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
    Popiela T; Kulig J; Czupryna A; Szczepanik AM; Zembala M
    Gastric Cancer; 2004; 7(4):240-5. PubMed ID: 15616772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
    Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of immunotherapy for advanced gastric cancer.
    Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
    Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep learning based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer.
    Liu Y; Chen W; Ruan R; Zhang Z; Wang Z; Guan T; Lin Q; Tang W; Deng J; Wang Z; Li G
    J Transl Med; 2024 May; 22(1):438. PubMed ID: 38720336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy.
    Shi Y; Liu X; Du J; Zhang D; Liu J; Chen M; Zhao J; Zhong W; Xu Y; Wang M
    Thorac Cancer; 2022 Jan; 13(2):219-227. PubMed ID: 34825500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.